Infectious Disease Clinics of North America volume 20, issue 3, P663-678 2006 DOI: 10.1016/j.idc.2006.06.006 View full text
William J. Steinbach, Thomas J. Walsh

Abstract: For more than 40 years, there has been limited progress in the treatment of invasive fungal infections. There are now numerous nuances to choosing the appropriate antifungal agent. Important advantages have been achieved in understanding the safety, tolerability, and pharmacokinetics of these agents. One of the most important aspects for successful management of pediatric invasive fungal infections is an understanding of the differences in the pharmacokinetics of the drugs in children and adults to offer optim…

expand abstract